Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label trial of ALXN1007 in non-criteria antiphospholipid syndrome manifestations
2013-003588-73Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olendalizumab in antiphospholipid syndrome (APS), Antiphospholipid Antibody Nephropathy (APLN), Thrombocytopenia and 1 more, sponsored by Alexion Pharmaceuticals. Primary endpoint: Safety and tolerability of ALXN1007. Started Oct 2013; status: terminated.
02
Drugs
olendalizumab
03
Conditions
antiphospholipid syndrome (APS)Antiphospholipid Antibody Nephropathy (APLN)ThrombocytopeniaCutaneous ulcer
Beyond the preview
Go deeper on 2013-003588-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003588-73.